FDA Budget Plan Signals Higher User Fees and New Drug Review Rules for Legal Teams
The FDA’s 2027 budget plan seeks higher user fees and major compliance shifts for regulated companies.
Why it matters: Legal teams at pharma, biotech, and device companies face new costs and compliance hurdles if the FDA’s proposed budget and policy changes advance. Redefined biosimilar approval standards and new pediatric drug incentives may require policy reviews, contract updates, and retooled risk assessment for regulatory teams.
- FDA’s 2027 budget totals $7.2 billion—up 3.3% from 2026.
- User fees would increase to $3.9 billion, with new funding for expedited drug review initiatives.
- Proposal eliminates the separate legal standard for 'interchangeable' biosimilars, simplifying substitution rules.
- The Rare Pediatric Disease Priority Review Voucher program would become permanent, encouraging pediatric drug development.
The U.S. Food and Drug Administration released its FY 2027 budget justification, seeking $7.2 billion in total funding—a 3.3% increase over FY 2026. Of this, $3.9 billion would come from user fees paid by regulated companies, while $3.3 billion would be government appropriations.
- Raised user fees: Companies could see higher annual costs, impacting budgets and agreement negotiations. The specifics by industry (drugs, devices, generics, tobacco) are still to be detailed.
- Biosimilar standard change: The FDA proposes removing the legal distinction for 'interchangeable' biosimilars, meaning that, if passed, all approved biosimilars could be substituted for reference biologics at the pharmacy. This would streamline pathways for product launches but may require updates to labeling, contracts, and compliance protocols. More details on biosimilar policy.
- Expedited clinical trials: FDA proposes a new optional, faster pathway for early-stage investigational studies—using preclinical and non-animal data. Legal teams may need to adapt to revised IND application standards and institutional research agreements.
- Rare Pediatric Disease PRV permanence: The agency would make permanent its Priority Review Voucher (PRV) program for rare pediatric diseases. This offers accelerated review to incentivize therapies in this area, expanding available compliance incentives for sponsors.
According to the FDA's budget overview, these measures target greater efficiency and better patient access. Legal counsel should begin mapping contract, policy, and due diligence updates ahead of the public comment period on the budget.
By the numbers:
- $7.2B — FDA’s proposed FY 2027 budget, up 3.3% from 2026
- $3.9B — Projected user fee revenue in 2027, a new high
- 2029 — Previous expiration year for the Rare Pediatric Disease PRV program
Yes, but: Congress must approve the budget and statutory changes before any proposal takes effect, so legal teams should monitor ongoing negotiations and prepare for possible revisions.
What's next: The FDA budget proposal will be subject to Congressional review, with potential for industry comment and statutory debate this year and into 2025.